In the News

A thought leadership article authored by Jenny Lee and Gene Chieh, investigating how biosimilars have gained momentum in a growing number of markets.

An interview with Nicole Cowan covering the new biomarker-driven landscape in clinical trials and the nuances of drug-diagnostics co-development programs.

ICON expert Gretchen Goller considers social media outreach's beneficial effect on patient connectivity to date in the October 2019 edition of PharmaVoice.

A thought leadership article authored by EB McLindon, discussing how making clinical research easier for the site can also make life easier for sponsors.

Andrew Roche discusses the challenges of delayed diagnosis, and under diagnosis, of NASH, the impact on NASH clinical trials, and important NASH endpoints being considered.

ICON boosts its hybrid clinical trial and site support services with the acquisition of Symphony Clinical Research, a provider of in-home and alternate site services.

A thought leadership article authored by Peter Schueler, exploring how the series of failures in Alzheimer’s disease research has provided insights into the disease pathology, study methodologies and - as a consequence – in the design of future development programmes for anti-Alzheimer medications.

The application of AI and machine learning in establishing a treatment’s value proposition is still a relatively new concept in pharma. Learn more in this article.

Will Maier and Kelly Franchetti discuss orphan drugs and patients' role in clinical trials as demand in the market increases.

A thought leadership article authored by Tom O’Leary, exploring what can be done to help ensure return on investment in clinical trials.